Journal of pharmacy practice最新文献

{"title":"Case Report of an Uncommon Dermatologic Manifestation of Disseminated <i>Stenotrophomonas Maltophilia</i> Infection in a Patient With Aplastic Anemia.","authors":"Mei Qin Dong, Brynna Crovetto, Tania Kupferman","doi":"10.1177/08971900261416805","DOIUrl":"10.1177/08971900261416805","url":null,"abstract":"<p><p>We present a case of ecthyma gangrenosum caused by <i>Stenotrophomonas maltophilia</i> in an immunocompromised patient with aplastic anemia and on antithymocyte globulin therapy, cyclosporine, and methylprednisolone treatment. We also conducted a brief literature review on ecthyma gangrenosum caused by <i>Stenotrophomonas maltophilia</i> to determine optimal treatment and expected duration of therapy for infection management. This report highlights the key clinical challenges in determining optimal treatment duration for this uncommon condition taking into account underlying host factors.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"464-471"},"PeriodicalIF":1.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of Artificial Intelligence in Pharmacy Education: A Scoping Review.","authors":"Ronald Watema-Lord, Chiranjeev Sanya","doi":"10.1177/08971900261491254","DOIUrl":"https://doi.org/10.1177/08971900261491254","url":null,"abstract":"<p><p>Artificial intelligence (AI) shows emerging potential in pharmacy education that it fundamentally enhancing the way students learn, practice, and apply clinical knowledge. With AI-driven adaptive learning systems, instruction becomes highly personalized, catering to individual learning styles and needs. This scoping review seeks to comprehensively synthesize the current literature on the application of artificial intelligence (AI) in pharmacy education, while also identifying gaps that demand further investigation. This scoping review was conducted in accordance with methodological guidance from the Joanna Briggs Institute. The literature search aimed to identify peer-reviewed publications in English in PubMed, Embase, and Scopus, which were searched from inception to August 7, 2025. Two reviewers independently completed title, abstract, and full-text screening against inclusion criteria. Data extracted were used to describe the body of literature using descriptive and qualitative approaches. A total of seven studies have been identified that explore the role of AI in pharmacy education. Five studies focus on how AI can change teaching and learning, while one study focuses on its capability to predict academic performance for admissions. The final study critically evaluates the benefits and limitations of employing AI text generation, particularly ChatGPT, highlighting its relevance and implications for the future of pharmacy education. At present, the number of publications exploring the application of AI in pharmacy education is quite limited. This presents significant challenges, including the necessity for faculty expertise and time, the restricted generalizability of available tools, insufficient outcomes data, and various legal and ethical considerations.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261491254"},"PeriodicalIF":1.0,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148990422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significant Publications on Infectious Diseases Pharmacotherapy in 2025.","authors":"Vy N Quach, Khadija Thomas, Kevin Lin, Christy P Su, Hiba Al Shaikhli, Adenike Olabode, Nancy N Vuong, Nhi Nguyen","doi":"10.1177/08971900261486586","DOIUrl":"https://doi.org/10.1177/08971900261486586","url":null,"abstract":"<p><p>This review provides summarization of the most significant infectious diseases (ID) pharmacotherapy articles published in peer-reviewed literature in 2025. Members of the Houston Infectious Diseases Network (HIDN) nominated notable articles providing significant contributions to ID pharmacotherapy in 2025. Article nominations included those pertaining to general ID and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) pharmacotherapy. To aid selection of the most notable articles of 2025, a survey was created and distributed to members of the Society of Infectious Diseases Pharmacists (SIDP). A total of 32 articles were nominated by HIDN/SIDP members, 26 articles related to general ID pharmacotherapy and 6 articles focusing on HIV/AIDS. Of the 212 SIDP members who participated in the survey, there were 101 recorded votes for the top 10 general ID pharmacotherapy articles and 40 votes recorded for the top HIV/AIDS article. The most notable publications are summarized. Ongoing research continues to discover findings that enhance antimicrobial stewardship and inform best practices in infectious diseases. From over 2000 articles published on PubMed using the keywords \"infectious diseases,\" \"HIV,\" \"pharmacotherapy,\" and \"anti-infective,\" this review highlights and summarizes the most influential ID publications with aims to update clinicians on potentially practice-changing ID pharmacotherapy publications from 2025.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261486586"},"PeriodicalIF":1.0,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case Report of Laminated Left Ventricular Thrombus in Acute Decompensated Heart Failure: Pharmacotherapeutic Considerations for Anticoagulation.","authors":"Anthony Acosta, Travis Yamanaka, Felicia Tan, Akrum Elshazali, Zane Elfessi","doi":"10.1177/08971900261483511","DOIUrl":"https://doi.org/10.1177/08971900261483511","url":null,"abstract":"<p><p>Left ventricular (LV) thrombus is a known complication of severe systolic dysfunction and is associated with an increased risk of systemic embolization. Optimal pharmacotherapeutic management remains an area of clinical uncertainty, particularly when thrombus morphology suggests lower embolic potential. A 56-year-old man with multiple cardiovascular risk factors presented with progressive dyspnea, anasarca, and hypoxic respiratory failure. Cardiac imaging demonstrated severe biventricular dysfunction (ejection fraction <20%) and a large, laminated, nonmobile apical LV thrombus. Concurrent findings included congestive hepatopathy with ascites and a small pulmonary embolism. Based on thrombus morphology and clinical stability, systemic anticoagulation was initiated without invasive intervention. The patient improved with aggressive diuresis, guideline-directed medical therapy for heart failure, and therapeutic anticoagulation. This case highlights pharmacotherapeutic considerations in the management of laminated LV thrombus, including the role of thrombus morphology in risk stratification, anticoagulant selection, and timing of therapy initiation. Early recognition and coordinated interdisciplinary management can support safe, noninvasive treatment strategies in complex heart failure presentations. In addition, this case highlights the importance of collaborative practice and pharmacist-guided anticoagulation strategies.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261483511"},"PeriodicalIF":1.0,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148929748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Heparin-Induced Thrombocytopenia With Plasmapheresis and IVIG Prior to Heart Transplantation: A Case Report.","authors":"Natalie McCourt, Kaitlin Blotske, Joseph Wenninger, Toby Trujillo, Gemlyn George","doi":"10.1177/08971900261481574","DOIUrl":"https://doi.org/10.1177/08971900261481574","url":null,"abstract":"<p><p><b>Background:</b> Heparin-Induced Thrombocytopenia (HIT) is a serious immune-mediated complication characterized by anti-platelet factor 4 (PF4)/heparin antibodies that activate platelets, causing thrombocytopenia and a paradoxical prothrombotic state. Management requires immediate heparin discontinuation and alternative anticoagulation due to thrombotic risks. <b>Case Presentation:</b> We report a 36-year-old pregnant female with heart failure who developed HIT after heparin exposure during extracorporeal membrane oxygenation (ECMO) support and was subsequently evaluated for heart transplantation. Confirmed HIT led to switching anticoagulation to bivalirudin. Prior to transplantation, where intraoperative heparin is standard, she underwent plasmapheresis (PLEX) followed by intravenous immunoglobulin (IVIG) and corticosteroids to reduce circulating HIT antibodies. This immune-modulating approach enabled safe intraoperative heparin use without thrombotic complications. Post-transplant HIT assays were negative, with platelet recovery and stable coagulation parameters. <b>Discussion:</b> This case demonstrates that combined PLEX and IVIG can effectively lower pathogenic HIT antibodies, permitting necessary heparin administration in critical settings like heart transplantation. <b>Conclusion:</b> Given the lack of standardized guidelines for managing HIT when heparin exposure is unavoidable, this report highlights a promising strategy to mitigate risks and underscores the need for further research to optimize care in such complex clinical scenarios.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261481574"},"PeriodicalIF":1.0,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148919586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refractory Vasoplegia Following Nimodipine Administration in Aneurysmal Subarachnoid Hemorrhage: A Case Series.","authors":"Brooke Lajeunesse, Catherine Stout, Stephanie McGovern, Patrick Scott Martindale, Dayoung Shim, Colleen Barthol, Paola Martinez","doi":"10.1177/08971900261486909","DOIUrl":"https://doi.org/10.1177/08971900261486909","url":null,"abstract":"<p><p><b>Introduction:</b> Following aneurysmal subarachnoid hemorrhage (aSAH), approximately 30% of patients experience delayed cerebral ischemia (DCI). Nimodipine, a cerebroselective dihydropyridine calcium channel blocker, reduces this risk of DCI with <5% of patients experiencing hypotension or bradycardia. We review four patients admitted to our Neurosciences Intensive Care Unit following aSAH who developed nimodipine-induced refractory vasoplegia. We discuss these four cases and detail the interventions used to counter their bradycardia and hypotension. <b>Methods:</b> We performed a retrospective chart review to examine vasopressor use and interventions required to combat hypotension and bradycardia as well as patient demographics and comorbidities to identify risk factors for nimodipine-induced vasoplegia. Similar case studies were reviewed. We performed a literature search to suggest treatment options for nimodipine toxicity and assess the risk of Nimodipine dose adjustments in possibly increasing DCI occurrence. <b>Results:</b> Patients required 6.5 medications on average to treat vasoplegia. Transvenous pacing and intubation were required for two patients. On average, vasoplegia lasted 18 hours and patients were slowly weaned off vasopressors. Risk factors for vasoplegia include liver and kidney disease. Nimodipine formulation may contribute to vasoplegia. Dose adjustments of nimodipine may increase risk of DCI. <b>Conclusion:</b> In our literature review, nimodipine is generally well-tolerated and reduces DCI. Mild to moderate hypotension requiring vasopressor support should be expected. In cases of refractory vasoplegia resulting in cardiovascular collapse, we recommend cessation of nimodipine and treating as calcium channel blocker toxicity along with the use of nitric oxide scavengers given nimodipine's mechanism of action and the mechanism of vasoplegia.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261486909"},"PeriodicalIF":1.0,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of a Ready-To-Use Vasopressin Product Availability in Automatic Dispensing Cabinets on Outcomes in Septic Shock.","authors":"Sarah E Pieterick, Erin D Wieruszewski, Kristen Kannel, Ross Dierkhising, Erica D Wittwer, Patrick M Wieruszewski","doi":"10.1177/08971900261486608","DOIUrl":"https://doi.org/10.1177/08971900261486608","url":null,"abstract":"<p><p>Prolonged durations of hypotension during septic shock promote organ injury and mortality. Empirical evidence suggests that earlier vasopressin initiation may improve outcomes in septic shock. The objective of this study was to determine the effect of a ready-to-use vasopressin formulation availability in intensive care unit automated dispensing cabinets on outcomes in septic shock. This was a pre-post quasi experimental study of adults admitted for septic shock who received vasopressin as a second line vasopressor after norepinephrine. Inverse probability of treatment weighting with propensity scores was used to balance baseline covariates between those who received the ready-to-use vasopressin product and the traditional pharmacy-compounded vasopressin product. Outcomes included time from vasopressin order to administration, time to target mean arterial pressure, length of stay, and mortality. A total of 1104 patients with septic shock were included. After propensity score adjustment, the ready-to-use group was associated with faster time to vasopressin administration (17 vs 41 min, <i>P</i> < 0.001), faster time to target mean arterial pressure (hazard ratio 1.29, 95% CI 1.14 to 1.47, <i>P</i> < 0.001), and a shorter length of intensive care unit stay (hazard ratio 1.23, 95% CI 1.06 to 1.43, <i>P</i> = 0.006) as the compounded group. Mortality was not significantly different. In patients with septic shock, availability of a ready-to-use vasopressin product in the intensive care unit automated medication dispensing cabinet was associated with faster time to administration, improved time to target mean arterial pressure, and reduced duration of intensive care.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261486608"},"PeriodicalIF":1.0,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148886973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ekbom's Delusional Parasitosis Related to Pramipexole and Amantadine Use: A Case Report.","authors":"Helen C Pervanas, Laura R Daly","doi":"10.1177/08971900261486915","DOIUrl":"https://doi.org/10.1177/08971900261486915","url":null,"abstract":"<p><p>Pramipexole is a dopamine agonist used for the treatment of Parkinson's disease and restless leg syndrome. Amantadine is an antiviral agent with dopaminergic action that is approved for the treatment of motor symptoms associated with Parkinson's disease. This case report describes a patient with delusional parasitosis associated with concurrent use of pramipexole and amantadine. A 71-year-old man with a history of multiple sclerosis and Parkinson's disease presented with delusional parasitosis 4 months after his dose of pramipexole was increased from 0.75 mg/day to 4.5 mg/day. He was admitted to the geriatric psychiatric unit after his stool samples were found to be negative for parasites. A pharmacist evaluated his medications and noted that pramipexole and amantadine were independently associated with delusional parasitosis. Pramipexole and amantadine were subsequently discontinued, the patient was discharged and delusions completely resolved 4 months post-discontinuation. Concomitant use of pramipexole and amantadine may have led to delusional parasitosis. A literature review suggests that delusional parasitosis may be linked to striatal dopamine transporter dysfunction. In this case, the Naranjo Probability Score indicated that a drug-induced adverse event was \"probable\". The effects of these medications may have been enhanced by the patient's advanced age and the administration of pramipexole at the maximum recommended dose. Delusional parasitosis can occur in patients receiving concomitant treatment with pramipexole and amantadine. Patients receiving high doses of these agents in combination with other risk factors such as advanced age and impaired renal function should be monitored for symptoms of delusional parasitosis.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261486915"},"PeriodicalIF":1.0,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148886958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clevidipine for Nicardipine Resistant Hypertension in Neurocritically Ill Patients.","authors":"J Tyler Haller, Christian Eslinger, Nicholas Nelson, Anusha Mangalampalli, Aditya Kumar, Chia-Ling Phuah, Lindsey Stubbs, Abigail Tittle, Sarah Sternbach, Diane McLaughlin","doi":"10.1177/08971900261483494","DOIUrl":"https://doi.org/10.1177/08971900261483494","url":null,"abstract":"<p><p>Acute hypertension is common in acute brain injuries and contributes to increased morbidity and mortality. The optimal agent to manage acute hypertension is unclear, though most critically ill patients in the Neuro Intensive Care Unit (Neuro ICU) are managed with nicardipine as a first line agent. If hypertension is inadequately controlled despite the maximal dose of nicardipine, few other agents exist that are both safe and efficacious. Clevidipine may be an optimal agent for nicardipine refractory hypertension. This retrospective cohort study included acute brain injured patients that were unable to achieve blood pressure goals despite maximal doses of nicardipine and were switched to clevidipine. The primary outcome was to evaluate the percentage of patients that achieved systolic blood pressure goals within 1 hour of clevidipine initiation. Secondary outcomes included hypotension, need for vasopressors, and development of tachycardia. Additional outcomes included duration of antihypertensive infusions and administration of as-needed hypertension medications. Out of 410 screened patients, 66 were included (median age 53.7 years, 43.9% female). Patients were at maximum nicardipine dose (15 mg/hr) when clevidipine was initiated in 91% of cases. Among those included, 77.3% of patients were unable to achieve goal blood pressure while on nicardipine therapy. Goal blood pressure was able to be achieved within 1 hour in 84.8% of patients receiving clevidipine. Adverse effects were minimal, with only 4 (6%) patients experiencing hypotension and 4 (6%) patients developing tachycardia within 12hrs of clevidipine initiation. The median duration of clevidipine infusion was 23.9 hours. Clevidipine appears to be an effective, safe alternative agent in patients that are unable to achieve blood pressure goals with nicardipine infusion. Future prospective, multicenter studies are needed to validate these findings and assess long-term neurological outcomes. Clinicians managing nicardipine-refractory hypertension in neurocritically ill patients may consider clevidipine as a structured second-line option pending such evidence.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261483494"},"PeriodicalIF":1.0,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148813416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gaps Between Intended Learning and Practice in PGY1 Pharmacy Residency Programs: Alignment of Training Experiences With Accreditation Standards.","authors":"Sharmon P Osae, Daniel B Chastain","doi":"10.1177/08971900261480294","DOIUrl":"https://doi.org/10.1177/08971900261480294","url":null,"abstract":"<p><p>Postgraduate Year One (PGY1) pharmacy residency programs are critical for developing clinically advanced pharmacists equipped with the skills necessary to improve patient care. However, alignment between intended training experiences, accreditation standards, and real-world implementation remains variable. Competency development in research and interprofessional collaboration may be compromised by operational demands such as central staffing or inconsistent communication practices. A 2020 multisite survey of University of Georgia-affiliated PGY1 programs revealed that while research time was universally allotted, 50% of residents reported being reassigned to other responsibilities during this period. Additionally, less than half of preceptors noted that pulling residents for staffing negatively impacted rotation goals. Discrepancies were also identified in perceptions of interprofessional communication. These findings support the need for intentional program design that protects educational integrity, ensures competency development, and prepares residents to meet the demands of modern pharmacy practice.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261480294"},"PeriodicalIF":1.0,"publicationDate":"2026-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}